

RESEARCH ARTICLE

Open Access

# Burden of rotavirus gastroenteritis in the Middle Eastern and North African pediatric population

Hanane Khoury<sup>1\*</sup>, Isla Ogilvie<sup>1</sup>, Antoine C El Khoury<sup>2</sup>, Yinghui Duan<sup>3</sup>, Mireille M Goetghebeur<sup>1</sup>

## Abstract

**Background:** Rotavirus gastroenteritis (RVGE) is the most common cause of severe childhood diarrhea worldwide. Objectives were to estimate the burden of RVGE among children less than five years old in the Middle East (Bahrain, Iran, Iraq, Israel, Jordan, Kuwait, Oman, Qatar, Saudi Arabia, Syria, UAE, Yemen), North Africa (Algeria, Egypt, Libya, Morocco, Tunisia) and Turkey.

**Methods:** A comprehensive literature search was conducted in major databases on the epidemiology and burden of rotavirus among children less than five years old between 1999 and 2009. Data from each country was extracted and compared.

**Results:** The search identified 43 studies. RVGE was identified in 16-61% of all cases of acute gastroenteritis, with a peak in the winter. RVGE-related hospitalization rates ranged from 14% to 45%, compared to 14%-28% for non-RVGE. Annually, RVGE caused up to 112 fatalities per 100,000 in certain countries in the region. Hospitalization costs ranged from \$1.8 to \$4.6 million annually, depending on the country. The most recent literature available showed that G1P[8] was the most prevalent genotype combination in 8 countries (range 23%-56%). G2P[4] was most prevalent in 4 countries (26%-48%). G9P[8] and G4P[8] were also frequently detected.

**Conclusions:** RVGE is a common disease associated with significant morbidity, mortality, and economic burden. Given the variety and diverse rotavirus types in the region, use of a vaccine with broad and consistent serotype coverage would be important to help decrease the burden of RVGE in the Middle East and North Africa.

## Background

Rotavirus remains the most common cause of severe childhood diarrhea worldwide and of diarrheal mortality in developing countries [1]. The main symptoms of rotavirus gastroenteritis (RVGE) are fever, abdominal pain, lethargy, diarrhea and vomiting that may lead to hypovolemic shock and dehydration [2,3]. Severe cases may lead to death [4]. The World Health Organization (WHO) estimates that 527,000 children under the age of five years die of rotavirus disease each year [5]. Children in the poorest countries account for 82% of rotavirus deaths [6].

Rotavirus is transmitted by the fecal-oral route [2]. Infection rates for rotavirus are highest in children under five years of age, with 95% of children between the age of three and five years affected [7]. There is seasonality to

rotavirus infection, with the majority of cases in temperate climates occurring in the winter months between November and February [2,8]. Seasonality in tropical and developing countries is less marked [7].

Three of the seven sero-groups of rotavirus identified affect humans, known as groups A-C. The most dominant, group A, causes diarrheal diseases worldwide [2]. Group A rotaviruses are classified into G and P-types, which are determined by the two outer layer viral proteins, VP7 and VP4, respectively. These two proteins elicit neutralizing antibody responses and therefore, protection from infection and disease is believed to be type-specific [9]. Rotaviruses are ubiquitous in the animal kingdom, and therefore, interspecies transmission and more importantly, exchange of genetic material between animal and human strains through re-assortment can lead to the emergence of novel rotavirus strains of epidemiological significance [9].

The incidence of infection with particular group A rotavirus serotypes and genotypes varies between

\* Correspondence: hanane\_khoury@biomedcom.org

<sup>1</sup>BioMedCom Consultants inc., 1405 TransCanada Highway, Suite 310, Montreal, Quebec, H9P 2V9, Canada

Full list of author information is available at the end of the article

geographical areas during a rotavirus season, and from one season to the next [10]. Globally, viruses carrying either G1, G2, G3, G4, G9 and P[4] or P[8] are the most common causes of rotavirus disease in humans. G12 is also recognized as an emergent serotype, that may become important in human disease [11].

Often, children suffering from RVGE require outpatient medical care, but in the presence of dehydration, admission to emergency or hospitalization and intravenous rehydration are necessary. Each year worldwide, rotavirus causes approximately 111 million episodes of gastroenteritis requiring only home care, 25 million office visits, and 2 million hospitalizations [6]. By the age of five years, nearly every child will have an episode of RVGE, one in five will visit a clinic, and one in 65 will be hospitalized [6]. Thus, RVGE imposes a heavy burden, not only by incurring direct medical costs, but also indirect costs due to productivity loss and other expenses [3,12,13]. Currently available rotavirus vaccines protected against severe RVGE and were well tolerated; the implementation of immunization programs would be expected to reduce disease burden [3].

Burden of illness data specific to the Middle East and North Africa is limited. The purpose of this study was to conduct a comprehensive literature review on the burden of rotavirus acute gastroenteritis on the pediatric population in these regions.

## Methods

### Literature search strategy

To identify and retrieve articles pertaining to the impact of rotavirus infection on the pediatric population ( $\leq 5$  years, unless otherwise specified) in the Middle East and North Africa, a comprehensive literature search was conducted in the National Library of Medicine's Pubmed, the Center for Disease Control (CDC) rotavirus global surveillance ([http://www.cdc.gov/rotavirus/global\\_surveillance/surveillance.htm](http://www.cdc.gov/rotavirus/global_surveillance/surveillance.htm)), and the WHO (<http://www.who.int/nuvi/rotavirus/en/>). The search, limited to articles published from 1999 to 2009, covered the Middle East (Bahrain, Iran, Iraq, Israel Jordan, Kuwait, Oman, Qatar, Saudi Arabia, Syria, UAE, Yemen), North Africa (Algeria, Egypt, Libya, Morocco, Tunisia), as well as Turkey for its regional proximity. Search terms included: rotavirus, outcome\*, mortality, death, incidence, prevalence, serotype, strain, cost\*, economic\*, burden, and resource use. Reviews and case studies were excluded.

### Data extraction and analysis

For all studies, dates reported for data presented refer to the date when studies were conducted, which was often several years before the publication date.

In the case where several surveillance studies are published for a single country, a pooled average of the proportion of RVGE among cases of acute gastroenteritis was calculated and reported. Ranges across studies were also reported for each country. Where available, data on infection seasonality was collected and reported, in addition to variation over time in the proportion of RVGE.

Data was extracted for each serotype. Figures for distribution of rotavirus genotype combinations were taken from the most recent available data, except for Turkey. For this country, data from a prospective survey from 2004-2005 [14] was used to replace a more recent publication (2005-2006 Ceyhan study [15]), due to discrepancies in the serotype data reporting (combined serotyped data in the Ceyhan study [15] adds up to 113%). Where two studies from the same year and the same country showed a similar serotype distribution, a weighted average across the studies was calculated to present as one figure. All other figures were reported as originally described in the source documents.

Mortality data included annual fatalities and mortality rates per 100,000 population under five years of age. For health outcomes of rotavirus acute gastroenteritis, data was extracted on disease severity as measured by the 20-point Vesikari scoring system [16], and the severity and proportion of patients suffering from dehydration due to rotavirus acute gastroenteritis. The Vesikari scale is a numerical system used to assess RVGE disease severity, based on the duration and intensity of diarrhea and vomiting, intensity of fever and dehydration, and the need for treatment and hospitalization [16]. A Vesikari score  $\geq 11$  is indicative of severe disease.


For healthcare resource use data, the following parameters were extracted for comparison across countries: hospital admission rates, need for intravenous rehydration, and duration of hospital stay. Cost-of-illness data included direct medical costs, out-of-pocket expenditures, and indirect costs attributed to lost productivity by parents of children suffering from RVGE. Costs are reported in 2008 US dollars.

No statistical analyses were performed for this review.

## Results

### Studies included in this review

As shown in Figure 1, this literature search recovered 43 citations which contain relevant data pertaining to acute gastroenteritis associated with rotavirus infection on the following topics: incidence and proportion of RVGE among cases of acute gastroenteritis ( $n = 37$  studies), serotype distribution ( $n = 25$ ), mortality ( $n = 1$ ), disease severity and outcomes ( $n = 9$ ), healthcare resource use ( $n = 11$ ), and costs ( $n = 2$ ). A summary of data sources by country is presented in Table 1.



### Epidemiology of rotavirus acute gastroenteritis

Data on the proportion of RVGE was available from the following countries: Egypt [17-21], Iran [18,22-27], Iraq [18,28], Jordan [18,29], Kuwait [30], Libya [18,31,32], Morocco [18,33], Oman [18,34,35], Saudi Arabia [36-40], Syria [18], Tunisia [18,41-46], Turkey [14,15,47-50], and Yemen [18]. No studies were found from Algeria, Bahrain, Israel, Qatar, and the United Arab Emirates. Most studies contained data on the proportion of RVGE rather than RVGE incidence. Only one study contained incidence data [21].

### Incidence

In Egypt, a population-based cohort study of children under three years of age reported age-related incidence of 0.61 rotavirus diarrheal episodes per person-year between 1995 and 1996 [21]. In this cohort, age-related incidence was highest in children aged 6 to 11 months.

### Proportion and seasonality of RVGE

When looking at the most recent studies that report data on the proportion of RVGE for children under five years of age in Middle Eastern and North African countries, the proportion of RVGE among cases of acute gastroenteritis ranged from 16% to 61% per year (Figure 2). Among the countries with the lowest proportion of RVGE

(16% to 23%) were Saudi Arabia [36-40], Tunisia [18,41-46], and Egypt [17-19,51]. Those with the highest proportion of RVGE included Syria (61%) [18], Oman (50%) [18,34,35], and Kuwait (44%) [30]. One study covered the WHO Eastern Mediterranean region as a whole, including many of the above countries (Egypt, Iran, Iraq, Jordan, Libya, Morocco, Oman, Syria, Tunisia, and Yemen) as well as Afghanistan and Sudan [18]. In this study, the overall annual prevalence of RVGE among reported episodes of gastroenteritis in children under five years of age was 42% [18].

A number of countries reported seasonality data including Egypt [19,21], Iran [22,23,26,27], Libya [31], Morocco [33], Oman [34], Saudi Arabia [37], Tunisia [42,45,46], and Turkey [14,15,49,50]. For most of these countries, the peak season for rotaviral gastroenteritis is in the winter from November to April. The exception to this is Egypt where rotaviral infection peaks in July to November [19,21].

### Variation in the proportion of RVGE over time

As illustrated in Figure 3, the proportion of RVGE among acute gastroenteritis cases appears to have increased over time in Egypt (from 8% to 42% between 2000 and 2007) [18,19] and Iran (from 15% in 2003-2004 to 59% in

**Table 1 Literature capture and data sources by country**

| Country       | Epidemiology |                   |               | Genotype combination data | Morbidity and Mortality |                   | Disease Burden |       |
|---------------|--------------|-------------------|---------------|---------------------------|-------------------------|-------------------|----------------|-------|
|               | Incidence    | Proportion RVGE   | Seasonality   |                           | Disease severity        | Mortality         | Resource use   | Costs |
| Multicountry* |              | [18] <sup>†</sup> |               |                           |                         | [55] <sup>‡</sup> |                |       |
| Algeria       |              |                   |               |                           |                         | [55]              |                |       |
| Bahrain       |              |                   |               |                           |                         | [55]              |                |       |
| Egypt         | [21]         | [17-21]           | [19,21]       | [17,17,18,18,21,53]       | [19,21,51]              | [55]              | [19,51]        |       |
| Iran          |              | [18,22-27]        | [22,23,26,27] | [18,22,26]                |                         | [55]              | [25]           |       |
| Iraq          |              | [18,28]           |               | [28]                      |                         | [55]              |                |       |
| Israel        |              |                   |               | [52]                      |                         | [55]              | [52,57]        | [52]  |
| Jordan        |              | [18,29]           |               | [18]                      | [29]                    | [55]              | [29]           |       |
| Kuwait        |              | [30]              |               | [30]                      |                         | [55]              |                |       |
| Libya         |              | [18,31,32]        | [31]          | [32]                      |                         | [55]              |                |       |
| Morocco       |              | [18,33]           | [33]          | [18,33]                   | [33]                    | [55]              | [33]           |       |
| Oman          |              | [18,34,35]        | [34]          | [18,34,35]                |                         | [55]              | [34]           | [34]  |
| Qatar         |              |                   |               |                           |                         | [55]              |                |       |
| Saudi Arabia  |              | [36-40]           | [37]          | [36-38]                   |                         | [55]              |                |       |
| Syria         |              | [18]              |               |                           |                         | [55]              |                |       |
| Tunisia       |              | [18,41-46]        | [42,45,46]    | [41,44,44,46]             | [42]                    | [55]              |                |       |
| Turkey        |              | [14,15,47-50]     | [14,15,49,50] | [14,15,48]                | [15,47,50]              | [55]              | [15,47,50]     |       |
| UAE           |              |                   |               |                           |                         | [55]              |                |       |
| Yemen         |              | [18]              |               | [18]                      |                         | [55]              |                |       |

\*Where country-specific data was available within a multicountry study, it has been extracted. Therefore, the relevant reference has been added to individual countries above.

<sup>†</sup>Egypt, Iran, Iraq, Jordan, Libya, Morocco, Oman, Syria, Tunisia, and Yemen.


<sup>‡</sup>All countries.

2006-2007) [22,27]. Proportion of RVGE in Saudi Arabia has fallen from 35% in 1995-1996 to around 12% since 2002-2003 [38,40]. Proportion of RVGE in the other countries for which data over time was available has remained relatively stable.


**Rotavirus genotype combinations in the Middle East and North Africa**

*Distribution of genotype combinations*

As shown in Figure 4, G1P[8] was the most prevalent genotype combination in eight of the 14 countries for



**Figure 2 Mean overall proportion of rotavirus gastroenteritis (% of reported acute gastroenteritis cases) by country.**



which recent data was available (Israel [52], Iraq [28], Kuwait [30], Libya [32], Morocco [33], Saudi Arabia [37], Tunisia [44], and Turkey [14]), with a proportion ranging from 23% to 56% of all genotyped samples. G2P [4] was the most prevalent genotype combination in four countries (Egypt [17,18], Jordan [18], Oman [18,34], and Yemen [18]; range 26%-48%), and was detected in every country except Tunisia. G9P[8] was detected in 10 of the 14 countries for which there was literature available (Egypt [17,18,53], Israel [52], Iraq [28], Kuwait [30], Libya [32], Morocco [18,33], Oman [35], Saudi Arabia [36-38], Tunisia [41,44], and Turkey [14,15,48]), and was highly prevalent in Morocco [33] and Libya [32] (31% and 34% of genotype combinations, respectively). G4P[8] was most prevalent in Iran [18] (27% of genotyped samples, respectively), and was present in Iraq [28], Kuwait [30], Tunisia [44,46], Turkey [14], and Yemen [18] (proportion range 2%-18%).


Other genotype combinations were also present in multiple countries as follows. G1P[4] (Egypt, Israel, Jordan, Kuwait, Oman, Tunisia, Turkey and Yemen; proportion range 0.2%-14%); G1P[6] (Egypt, Iraq, Jordan, Libya, Morocco, Pakistan, Turkey, and Tunisia; range 1%-14%); G3P[8] (Israel, Iran, Jordan, Kuwait, Saudi Arabia and Tunisia). Rarer genotype combinations, each present in six countries or fewer, accounted for 10% or less of the total genotype combinations (Table 2). Mixed genotype combinations, including G1G2 and G1G4, were detected in most countries (2%-25% of the total rotavirus positive samples). Non-typable and partially typed serotypes accounted for a significant proportion

of serotype samples, ranging between 5% and 20% for non-typable, and 5% to 19% for partially typable samples.

#### Evolution of genotype combinations over time

Studies from six countries reported distribution over time of fully genotyped samples from children ≤5 years of age: Egypt [17,18,21], Iran [18,22,26], Oman [18,34,35], Saudi Arabia [36,38], Tunisia [44], and Turkey [14,48] (Figure 5). In Egypt, the proportion of G2P [4] fell, and G1P[8] increased between 1995-1996 and 2006-2008 [17,18,21]. Over the same time frame, G9P[8] was detected (7%). In Iran, G1P[8] proportion declined, and G4P[8] became the most prevalent genotype combination in 2006-2008 [18,22,26]. In Saudi Arabia, there was a decrease in both G1P[8] and G9P[8] (16% to 11%), while G2P[4] increased from 2002-2003 to 2004-2005 [36,38]. In Tunisia, G1P[8] and G1P[6] were replaced by a variety of genotype combinations including G1P[4], G9P[8], and G3P[8] [44]. Finally in Turkey, the predominant genotype combination G1P[8] increased in proportion, while G4P[8] declined [14,15,48].

Two studies, both from Tunisia, covered the emergence of new serotypes in North Africa [41,46]. The earlier study by Trabelsi et al, described the emergence of a reassorted strain G1P[4] in the Sousse region in the 1998-1999 season. G1, G2, and G4 strains were prevalent at this time, with no detection of G3 or G9 [46]. The second, a prospective study of five hospitals in Eastern-Central Tunisia described the emergence of G9 serotypes during 2003-2005, further characterized as G9P[8] [41].




**Figure 4** Distribution of rotaviral genotype combinations in the Middle East and North Africa by country, most recent literature available. NB: "Other" includes the proportion of rare and mixed genotype combinations, and non- or partially-typable serotypes.

**Table 2** Rare genotype combinations from the Middle East and North Africa by country (recent studies)

| Serotype | Egypt   | Israel  | Iran    | Iraq  | Jordan  | Kuwait  | Morocco | Oman    | Saudi Arabia | Tunisia | Turkey  | Yemen   | n of countries |
|----------|---------|---------|---------|-------|---------|---------|---------|---------|--------------|---------|---------|---------|----------------|
|          | 2006-08 | 2007-08 | 2006-08 | 2006  | 2006-08 | 2005-06 | 2006-07 | 2006-08 | 2004-05      | 2004    | 2004-05 | 2006-08 |                |
| G2P[8]   | 5.96%   | 2.80%   | -       | -     | -       | 1.30%   | 0.70%   | -       | -            | -       | 1.60%   | 2.20%   | 6              |
| G4P[6]   | -       | -       | -       | 1.50% | -       | 1.30%   | -       | -       | -            | 3.80%   | -       | -       | 4              |
| G2P[6]   | 1.88%   | -       | -       | -     | 1.80%   | -       | 9%      | -       | -            | -       | -       | -       | 3              |
| G3P[4]   | -       | 7.40%   | -       | -     | -       | -       | -       | -       | -            | 3.80%   | 1.60%   | -       | 3              |
| G12P[8]  | -       | 4.60%   | -       | -     | -       | -       | -       | -       | 4%           | 1.90%   | -       | -       | 3              |
| G9P[4]   | -       | 0.90%   | -       | -     | -       | -       | -       | 2.9%    | -            | -       | 1.60%   | -       | 3              |
| G9P[6]   | -       | -       | -       | 1.50% | -       | -       | -       | -       | -            | -       | 3.10%   | -       | 2              |
| G12P[6]  | 6.96%   | -       | -       | -     | -       | -       | -       | -       | -            | -       | -       | -       | 1              |
| G3P[9]   | -       | -       | 0.78%   | -     | -       | -       | -       | -       | -            | -       | -       | -       | 1              |
| G2P[10]  | -       | -       | -       | -     | -       | -       | -       | 1.3%    | -            | -       | -       | -       | 1              |
| G1P[10]  | -       | -       | -       | -     | -       | -       | -       | 1.2%    | -            | -       | -       | -       | 1              |
| G3P[6]   | -       | -       | -       | -     | -       | -       | -       | -       | -            | 1.90%   | -       | -       | 1              |
| G4P[4]   | -       | -       | -       | -     | -       | -       | -       | -       | -            | 1.90%   | -       | -       | 1              |
| G8P[4]   | -       | -       | -       | -     | -       | -       | -       | -       | -            | -       | 1.50%   | -       | 1              |
| G1P[11]  | -       | -       | -       | -     | -       | -       | -       | -       | -            | -       | -       | 2.20%   | 1              |
| G9P[11]  | -       | -       | -       | -     | -       | -       | -       | -       | -            | -       | -       | 2.20%   | 1              |





**Figure 5** Distribution of rotaviral genotype combinations in the Middle East and North Africa over time, from recent literature. NB: "Other" includes the proportion of rare and mixed genotype combinations, and non- or partially typable serotypes.

### Morbidity and mortality due to rotavirus acute gastroenteritis

#### Disease severity

Data pertaining to disease severity and dehydration due to RVGE in the Middle East and North Africa was available from the following countries only: Egypt [19,21,51], Jordan [29], Morocco [33], Tunisia [42], and Turkey [15,47,50]. Dehydration was a common health outcome reported by all studies, affecting around 50% of children with RVGE [19,21,42,50,51]. In 3% to 25% of cases, dehydration was classified as severe [15,19,21,42,54]. Furthermore, disease severity, measured on the Vesikari scale, was explored by one study from Morocco [33] and three Turkish [15,47,50] studies. In Morocco, a prospective surveillance study of 345 hospitalized children with rotavirus estimated a median Vesikari score of 14 [33]; this score was significantly higher than the one obtained among children with non-RVGE ( $P = 0.03$ ). In Turkey, prospective hospital-based studies showed that between 37% and 90% of children with rotavirus had severe disease on the Vesikari scale [15,47,50].

#### Mortality

Information on mortality due to RVGE in the Middle East and North Africa was limited to the WHO report on death estimates from all countries of interest [55]. In


the countries covered in this study, fatalities due to RVGE ranged from a low of <10 per year (Bahrain, Israel, Kuwait, and Qatar) to a high of 4,723 per year (Iraq). This translates into annual mortality rates of 0 to 112 per 100,000 infants under five years of age (Figure 6) [55]. When the overall pediatric population below five years of age was considered, the average mortality rate from the 20 countries was estimated at 39 per 100,000 per year (17,766 rotavirus deaths per 45,437,000 children <5 years of age—estimate based on demographic indicators from UNICEF [56]).

#### Healthcare resource use

Overall, 11 studies reported healthcare resource use data from Egypt [19,51], Iran [25], Israel [52,57], Jordan [29], Morocco [33], Oman [34], and Turkey [15,47,50].

#### Hospital admissions

In Egypt, two hospital-based studies reported hospital admission rates due to RVGE among young children. This rate varied between 14% among children presenting with diarrhea at a hospital in Southern Egypt [51], and 45% among those presenting at two government referral hospitals in the Nile River Delta [19]. Hospitalization rates were 39% among toddlers with RVGE (<2 years) in Iran [25], and 31% among children younger



**Figure 6** Mortality due to rotavirus in the Middle East and North Africa by country.

than five years of age in Turkey [50]. Interestingly, the Turkish prospective survey, involving 920 patients admitted for acute gastroenteritis, found that rotavirus-positive gastroenteritis caused a significantly higher rate of hospital admissions versus non-RVGE (31% vs 14% non-RVGE;  $P < 0.01$ ) [50]. In Oman, a prospective hospital-based surveillance study estimated that, by age five years, one in 16 children will require hospitalization due to rotavirus [34].

#### **Intravenous rehydration**

At least 90% of hospitalized children with RVGE required intravenous rehydration in Morocco [33], Oman [34], and Turkey [15,47]. This figure was 63% in a prospective survey from Jordan [29], and 67% among children aged <18 months in Israel [57].

#### **Duration of hospital stay**

Data from three countries indicated that RVGE among young children required hospitalization of at least three days, as reported in a prospective surveillance study from Oman (median: 3 days) [34], and a population-based cohort study in Israel (mean:  $3.0 \pm 2.9$  days) [52]. In Turkey, the mean hospital duration was longer for RVGE than non-rotavirus disease ( $5.5 \pm 5.1$  days vs  $3.3 \pm 3.1$  days non-rotavirus) [50]. A prospective study of three pediatric departments in Israel reported that hospital stay was longer among younger children with nosocomial RVGE (3.5 vs 2.1 days for children <6 months old and those >26-48 months, respectively) [57]. In this study, hospital duration was 3.5 and 2.1 days for children <6 months and those between 36 and 48 months, respectively [57].

#### **Economic burden associated with RVGE**

Cost of illness data was limited to studies from Israel [52] and Oman [34]. In Israel, the total cost of hospitalization (direct medical costs) was estimated at 2008 US \$1,117 per patient for an average of three hospital days, for a total of \$4.59 million per year for all Israel patients [52]. One episode of RVGE was estimated to incur

out-of-pocket expenses of \$281, for a national annual estimate of \$1.15 million paid by parents (extra diapers, transportation, over-the-counter medications, special diet, medical consultations), and caused productivity loss of four to six days of work at a cost of \$476 per patient hospitalized, for a national annual estimate of \$1.95 million for indirect costs [52]. In Oman, Al Awaidy et al (2009) [34] estimated the direct cost for three days of hospitalization at \$539 per event, or \$1.80 million per year. Out-of-pocket and indirect costs were not reported in this study.

#### **Discussion**

Based on data collected from 44 studies in the Middle East and North Africa, this analysis shows that rotavirus imposes a heavy burden among children less than five years of age. Overall, the annual proportion of RVGE among reported episodes of pediatric gastroenteritis in the Middle East and North Africa region was 42% [18]. This figure is similar to a published estimate of the proportion of RVGE (43%) from a prospective multicountry study in Western Europe [58], further emphasizing the ubiquitous nature of the disease [7]. However, when Middle Eastern and North African countries were compared to each other, large variations in proportion of RVGE estimates were observed, with a low of 16%-23% reported in Saudi Arabia, Tunisia, and Egypt, and a high of 44%-61% in Syria, Oman, and Kuwait. These variations may reflect actual differences in RVGE proportion but may also be related to variations in study design, which limit comparability across countries.

A considerable amount of information on serotype distribution in the countries of interest was retrieved, highlighting the predominance of G1P[8] and G2P[4]. These genotype combinations are also predominant in Western Europe [59]. In the present study, the proportion of non-typable and partially typable genotype combinations varied widely across countries [22,26,36,37]. The reason for this discrepancy is not clear, although it



might be due to differences in study design and setting, or to laboratory practice differences from country to country.

Several studies assessed the evolution of serotype distribution over time and the emergence of new rotavirus strains in the Middle East and North Africa. All of these prevalent (G2P[4] [36,38], G4P[8] [18,22,26], G3P[8] [44]) and emerging (G9P[8] [17,18,21,41]; G1P[4] [46]) serotypes belong to the most commonly described strains of rotavirus that are responsible for gastroenteritis disease in humans [10]. Interestingly, G12, a recently emerging serotype detected in Europe, Asia, and the Americas [11,60,61], has not been reported in any of the studies captured in this review.

A wide inter-country variation was noticed in mortality rates due to RVGE, with the highest rates reported in Iraq and Yemen compared to less than one fatality in Bahrain, Israel, and Kuwait (Figure 6). Based on demographic indicators from UNICEF, the average annual mortality rate in the region was estimated at 39 per 100,000. This rate is considerably higher than in Europe, where rotavirus rarely results in child death (mortality rate below 10 per 100,000) [55]. These inter-country and inter-region variations are in agreement with previous reports showing that children in the poorest countries account for 82% of rotavirus deaths [6]. Because of data limitations, it cannot be concluded from this study whether differences in mortality rates are due to variations in clinical management of the disease.

The hospital admission rates and the use of intravenous rehydration were similar to European figures reported in the multicentre RVGE Epidemiology and Viral types in Europe Accounting for Losses in public health and society (REVEAL) study [62]. As well, the higher rates of hospitalization and higher disease severity for rotavirus versus non-rotavirus acute gastroenteritis reported in this review were in line with data reported in Western Europe [63].

Rotavirus cost information was very limited in the Middle East and North Africa. Per episode of RVGE, direct medical costs in the Middle East and North Africa (\$467 to \$1,117) were lower than those reported in Western Europe (ranging from 2008 US \$1,949 in the UK to \$2,398 in Sweden) [62].

Study limitations are worth mentioning. Most published articles retrieved in this study reported serotype and epidemiological data; information on the burden of RVGE in terms of mortality, morbidity, and economic burden was limited. This in turn restricted the evaluation of the global burden for the region. Most recent available data was considered to describe and compare serotype distribution across countries; however, the only available data was not necessarily recent and did not correspond to the same time frame in all countries.

For example, the only serotype information for Libya was published in 2000 [32], therefore conclusions on serotype distribution for this country may have changed, and comparison with 2008 data from other countries would be limited. Moreover, due to data limitations, a clear relationship between certain rotavirus genotypes and disease severity could not be established. Finally, variations in study setting and design may affect comparability of data.

## Conclusions

RVGE is a common disease associated with significant morbidity, mortality and costs in the Middle East and North Africa. The results of this study may be useful as background information to the planning and implementation of efficient vaccination programs. Given the variety and diverse rotavirus types in the region, a vaccine with broad and consistent serotype coverage would be important to help decrease the burden of RVGE in the Middle East and North Africa.

## Acknowledgements

The authors wish to thank Donna Rindress for her thoughtful comments. This study was sponsored by Merck & Co.

## Author details

<sup>1</sup>BioMedCom Consultants inc., 1405 TransCanada Highway, Suite 310, Montreal, Quebec, H9P 2V9, Canada. <sup>2</sup>Merck & Co, West Point, PA, 19486, USA. <sup>3</sup>Lehigh University, Bethlehem, PA, 18015, USA.

## Authors' contributions

HK & IO developed the search algorithm and drafted the manuscript. AEK, YD, and MMG participated in the design of the methodology and drafting of the manuscript. All authors read and approved the final manuscript.

## Competing interests

HK, IO, and MMG declare that they have no competing interests. AEK is an employee of Merck Sharp & Dohme Corp. and potentially owns stock and/or holds stock options in the Company. YD is a fellow at Lehigh University; her fellowship was funded by Merck & Co.

Received: 25 May 2010 Accepted: 7 January 2011

Published: 7 January 2011

## References

1. Widdowson MA, Steele D, Vojdani J, Wecker J, Parashar UD: **Global rotavirus surveillance: preparing for the introduction of rotavirus vaccines.** *J Infect Dis* 2009, **200**(Suppl 1):S1-S8.
2. Diggle L: **Rotavirus diarrhoea and future prospects for prevention.** *Br J Nurs* 2007, **16**(16):970-974.
3. Grimwood K, Lambert SB: **Rotavirus vaccines: opportunities and challenges.** *Hum Vaccin* 2009, **5**(2):57-69.
4. Parashar UD, Gibson CJ, Bresse JS, Glass RI: **Rotavirus and severe childhood diarrhea.** *Emerg Infect Dis* 2006, **12**(2):304-306.
5. Parashar UD, Burton A, Lanata C, Boschi-Pinto C, Shibuya K, Steele D, Birmingham M, Glass RI: **Global mortality associated with rotavirus disease among children in 2004.** *J Infect Dis* 2009, **200**(Suppl 1): S9-S15.
6. Parashar UD, Hummelman EG, Bresse JS, Miller MA, Glass RI: **Global illness and deaths caused by rotavirus disease in children.** *Emerg Infect Dis* 2003, **9**(5):565-572.
7. Parashar UD, Bresse JS, Gentsch JR, Glass RI: **Rotavirus.** *Emerg Infect Dis* 1998, **4**(4):561-570.

8. Gleizes O, Desselberger U, Tatchenko V, Rodrigo C, Salman N, Mezner Z, Giaquinto C, Grimprel E: **Nosocomial rotavirus infection in European countries: a review of the epidemiology, severity and economic burden of hospital-acquired rotavirus disease.** *Pediatr Infect Dis J* 2006, **25**(Suppl 1):S12-S21.
9. Iturriza-Gomara M, Kang G, Gray J: **Rotavirus genotyping: keeping up with an evolving population of human rotaviruses.** *J Clin Virol* 2004, **31**(4):259-265.
10. Iturriza-Gomara M, Green J, Brown DW, Ramsay M, Desselberger U, Gray JJ: **Molecular epidemiology of human group A rotavirus infections in the United Kingdom between 1995 and 1998.** *J Clin Microbiol* 2000, **38**(12):4394-4401.
11. Matthijnssens J, Rahman M, Ciarlet M, Van Ranst M: **Emerging Human Rotavirus Genotypes.** In *Viruses in the Environment*. Edited by: Palumbo E, Kirkwood C. Kerala, India: Research Signpost; 2009:171-219.
12. Soriano-Gabarro M, Mrukowicz J, Vesikari T, Verstraeten T: **Burden of rotavirus disease in European Union countries.** *Pediatr Infect Dis J* 2006, **25**(Suppl 1):S7-S11.
13. World Health Organization: **External review of burden of disease attributable to rotavirus.** World Health Organization; 2009 [http://www.who.int/immunization\_monitoring/burden/Rota\_virus\_Q5\_mortality\_estimates\_external\_review\_report\_2006\_may.pdf].
14. Bozdayi G, Dogan B, Dalgic B, Bostanci I, Sari S, Battaloglu NO, Rota S, Dallar Y, Nishizono A, Nakagomi O, Ahmed K: **Diversity of human rotavirus G9 among children in Turkey.** *J Med Virol* 2008, **80**(4):733-740.
15. Ceyhan M, Alhan E, Salman N, Kurugol Z, Yildirim I, Celik U, Keser M, Koturoglu G, Tezer H: **Multicenter prospective study on the burden of rotavirus gastroenteritis in Turkey, 2005-2006: a hospital-based study.** *J Infect Dis* 2009, **200**(Suppl 1):S234-S238.
16. Ruuska T, Vesikari T: **Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes.** *Scand J Infect Dis* 1990, **22**(3):259-267.
17. Kamel AH, Ali MA, El Nady HG, de Rougemont A, Pothier P, Belliot G: **Predominance and circulation of enteric viruses in the region of Greater Cairo, Egypt.** *J Clin Microbiol* 2009, **47**(4):1037-1045.
18. Teleb N: **Rotavirus Surveillance Network in the Eastern Mediterranean regional.** Presented at the 8th International Rotavirus Symposium; 2008 June 3-4 Istanbul; 2008.
19. Wierzbza TF, Abdel-Messih IA, Abu-Elyazeed R, Putnam SD, Kamal KA, Rozmajzl P, Ahmed SF, Fatah A, Zabedy K, Shaheen HI, Sanders J, Frenck R: **Clinic-based surveillance for bacterial- and rotavirus-associated diarrhea in Egyptian children.** *Am J Trop Med Hyg* 2006, **74**(1):148-153.
20. Antunes H, Afonso A, Iturriza M, Martinho I, Ribeiro C, Rocha S, Magalhaes C, Carvalho L, Branca F, Gray J: **G2P[4] the most prevalent rotavirus genotype in 2007 winter season in an European non-vaccinated population.** *J Clin Virol* 2009, **45**(1):76-78.
21. Naficy AB, Abu-Elyazeed R, Holmes JL, Rao MR, Savarino SJ, Kim Y, Wierzbza TF, Peruski L, Lee YJ, Gentsch JR, Glass RI, Clemens JD: **Epidemiology of rotavirus diarrhea in Egyptian children and implications for disease control.** *Am J Epidemiol* 1999, **150**(7):770-777.
22. Eesteghamati A, Gouya M, Keshtkar A, Najafi L, Zali MR, Sanaei M, Yaghini F, El Mohamady H, Patel M, Klena JD, Teleb N: **Sentinel hospital-based surveillance of rotavirus diarrhea in Iran.** *J Infect Dis* 2009, **200**(Suppl 1):S244-S247.
23. Modarres S, Rahbarmanesh AA, Karimi M, Modarres S, Motamedi-Rad M, Sohrabi A, Nasiri-Oskoi N: **Electrophoretic RNA genomic profiles of rotavirus strains prevailing among hospitalized children with acute gastroenteritis in Tehran, Iran.** *Arch Iran Med* 2008, **11**(5):526-531.
24. Kordidarian R, Kelishadi R, Arjmandfar Y: **Nosocomial infection due to rotavirus in infants in Alzahra Hospital, Isfahan, Iran.** *J Health Popul Nutr* 2007, **25**(2):231-235.
25. Samarbarfzadeh A, Tehrani EM, Makvandi M, Taremi M: **Epidemiological aspects of rotavirus infection in Ahwaz, Iran.** *J Health Popul Nutr* 2005, **23**(3):245-249.
26. Khalili B, Cuevas LE, Reisi N, Dove W, Cunliffe NA, Hart CA: **Epidemiology of rotavirus diarrhoea in Iranian children.** *J Med Virol* 2004, **73**(2):309-312.
27. Zarnani AH, Modarres S, Jadali F, Sabahi F, Moazzeni SM, Vazirian F: **Role of rotaviruses in children with acute diarrhea in Tehran, Iran.** *J Clin Virol* 2004, **29**(3):189-193.
28. Ahmed HM, Coulter JB, Nakagomi O, Hart CA, Zaki JM, Al Rabaty AA, Dove W, Cunliffe NA: **Molecular characterization of rotavirus gastroenteritis strains, Iraqi Kurdistan.** *Emerg Infect Dis* 2006, **12**(5):824-826.
29. Youssef M, Shurman A, Bougnoux M, Rawashdeh M, Bretagne S, Strockbine N: **Bacterial, viral and parasitic enteric pathogens associated with acute diarrhea in hospitalized children from North Jordan.** *FEMS Immunol Med Microbiol* 2000, **28**(3):257-263.
30. Marmash RW, Dalwai AK, Szucs G, Molla AM, Pacsa AS, Al Nakib W, Albert MJ: **Genotypic characterization of rotaviruses and prevalence of serotype-specific serum antibodies in children in Kuwait.** *Epidemiol Infect* 2007, **135**(8):1331-1337.
31. Ali MB, Ghenghesh KS, Aissa RB, Abuhelfaia A, Dufani M: **Etiology of childhood diarrhea in Zliten, Libya.** *Saudi Med J* 2005, **26**(11):1759-1765.
32. Cunliffe NA, Dove W, Bunn JE, Ben Ramadam M, Nyangao JW, Riveron RL, Cuevas LE, Hart CA: **Expanding global distribution of rotavirus serotype G9: detection in Libya, Kenya, and Cuba.** *Emerg Infect Dis* 2001, **7**(5):890-892.
33. Benhafid M, Youbi M, Klena JD, Gentsch JR, Teleb N, Widdowson MA, ElAouad R: **Epidemiology of rotavirus gastroenteritis among children <5 years of age in Morocco during 1 year of sentinel hospital surveillance, June 2006-May 2007.** *J Infect Dis* 2009, **200**(Suppl 1):S70-S75.
34. Al Awaidy SA, Bawikar S, Al Bousaidy S, Baqiani S, Al Abedani I, Varghese R: **Considerations for introduction of a rotavirus vaccine in Oman: rotavirus disease and economic burden.** *J Infect Dis* 2009, **200**(Suppl 1):S248-S253.
35. Al Lawati Z, Al Toubi M: **Community health & disease surveillance newsletter Oman.** Ministry of Health Oman; 2009 [http://www.moh.gov.om/reports/publications/Newsletter17-8.pdf].
36. Kheyami AM, Areeshi MY, Dove W, Nakagomi O, Cunliffe NA, Anthony HC: **Characterization of rotavirus strains detected among children and adults with acute gastroenteritis in Gizan, Saudi Arabia.** *Saudi Med J* 2008, **29**(1):90-93.
37. Kheyami AM, Nakagomi T, Nakagomi O, Dove W, Hart CA, Cunliffe NA: **Molecular epidemiology of rotavirus diarrhea among children in Saudi Arabia: first detection of G9 and G12 strains.** *J Clin Microbiol* 2008, **46**(4):1185-1191.
38. Tayeb HT, Dela Cruz DM, Al Qahtani A, Al Ahdal MN, Carter MJ: **Enteric viruses in pediatric diarrhea in Saudi Arabia.** *J Med Virol* 2008, **80**(11):1919-1929.
39. Ghazi HO, Khan MA, Telmesani AM, Idress B, Mahomed MF: **Rotavirus infection in infants and young children in Makkah, Saudi Arabia.** *J Pak Med Assoc* 2005, **55**(6):231-234.
40. el Sheikh SM, el Assouli SM: **Prevalence of viral, bacterial and parasitic enteropathogens among young children with acute diarrhoea in Jeddah, Saudi Arabia.** *J Health Popul Nutr* 2001, **19**(1):25-30.
41. Chouikha A, Fodha I, Bouslama L, Fredj MBH, Jaoua S, Boujaafar N: **Emergence and characterization of human rotavirus G9 strains in Tunisia.** *J Infect Dis* 2009, **200**(Suppl 1):S239-S243.
42. Sdiri-Loulizi K, Gharbi-Khelifi H, de Rougemont A, Chouchane S, Sakly N, Ambert-Balay K, Hassine M, Guediche MN, Aouni M, Pothier P: **Acute infantile gastroenteritis associated with human enteric viruses in Tunisia.** *J Clin Microbiol* 2008, **46**(4):1349-1355.
43. Al Gallas N, Bahri O, Bouratbeen A, Ben Haasen A, Ben Aissa R: **Etiology of acute diarrhea in children and adults in Tunis, Tunisia, with emphasis on diarrheagenic Escherichia coli: prevalence, phenotyping, and molecular epidemiology.** *Am J Trop Med Hyg* 2007, **77**(3):571-582.
44. Chouikha A, Fodha I, Noomen S, Bouzid L, Mastouri M, Peenze I, De Beer M, Dewar J, Geyer A, Sfar T, Gueddiche N, Messaadi F, Trabelsi A, Boujaafar N, Steele AD: **Group A rotavirus strains circulating in the eastern center of Tunisia during a ten-year period (1995-2004).** *J Med Virol* 2007, **79**(7):1002-1008.
45. Fodha I, Chouikha A, Peenze I, De Beer M, Dewar J, Geyer A, Messaadi F, Trabelsi A, Boujaafar N, Taylor MB, Steele D: **Identification of viral agents causing diarrhea among children in the Eastern Center of Tunisia.** *J Med Virol* 2006, **78**(9):1198-1203.
46. Trabelsi A, Peenze I, Pager C, Jeddi M, Steele D: **Distribution of rotavirus VP7 serotypes and VP4 genotypes circulating in Sousse, Tunisia, from 1995 to 1999: emergence of natural human reassortants.** *J Clin Microbiol* 2000, **38**(9):3415-3419.
47. Ciftci E, Tapisiz A, Ozdemir H, Guriz H, Kendirli T, Ince E, Dogru U: **Bacteraemia and candidaemia: A considerable and underestimated complication of severe rotavirus gastroenteritis.** *Scand J Infect Dis* 2009, 1-5.
48. Cataloluk O, Iturriza M, Gray J: **Molecular characterization of rotaviruses circulating in the population in Turkey.** *Epidemiol Infect* 2005, **133**(4):673-678.

49. Karadag A, Acikgoz ZC, Avci Z, Catal F, Gocer S, Gamberzade S, Uras N: **Childhood diarrhoea in Ankara, Turkey: epidemiological and clinical features of rotavirus-positive versus rotavirus-negative cases.** *Scand J Infect Dis* 2005, **37**(4):269-275.
50. Kurugol Z, Geylani S, Karaca Y, Umay F, Erensoy S, Vardar F, Bak M, Yaprak I, Ozkinay F, Ozkinay C: **Rotavirus gastroenteritis among children under five years of age in Izmir, Turkey.** *Turk J Pediatr* 2003, **45**(4):290-294.
51. El Mohamady H, Abdel-Messih IA, Youssef FG, Said M, Farag H, Shaheen HI, Rockabrand DM, Luby SB, Hajjeh R, Sanders JW, Monteville MR, Klens JD, Frenck RW: **Enteric pathogens associated with diarrhea in children in Fayoum, Egypt.** *Diagn Microbiol Infect Dis* 2006, **56**(1):1-5.
52. Muhsen K, Shulman L, Rubinstein U, Kasem E, Kremer A, Goren S, Zilberstein I, Chodick G, Ephros M, Cohen D: **Incidence, characteristics, and economic burden of rotavirus gastroenteritis associated with hospitalization of Israeli children <5 years of age, 2007-2008.** *J Infect Dis* 2009, **200**(Suppl 1):S254-S263.
53. Villena C, El Senousy WM, Abad FX, Pinto RM, Bosch A: **Group A rotavirus in sewage samples from Barcelona and Cairo: emergence of unusual genotypes.** *Appl Environ Microbiol* 2003, **69**(7):3919-3923.
54. Youssef M, Shurman A, Bougnoux M, Rawashdeh M, Bretagne S, Strockbine N: **Bacterial, viral and parasitic enteric pathogens associated with acute diarrhea in hospitalized children from northern Jordan.** *FEMS Immunol Med Microbiol* 2000, **28**(3):257-263.
55. World Health Organization: **Child rotavirus deaths.** World Health Organization; 2009 [[http://www.who.int/immunization\\_monitoring/burden/rotavirus\\_estimates/en/index.html](http://www.who.int/immunization_monitoring/burden/rotavirus_estimates/en/index.html)].
56. UNICEF: **Information by country and programme - Demographic indicators.** UNICEF; 2009 [<http://www.unicef.org/infobycountry/index.html>].
57. Waisbourd-Zinman O, Ben Zion S, Solter E, Scherf E, Samra Z, Ashkenazi S: **Hospitalizations for nosocomial rotavirus gastroenteritis in a tertiary pediatric center: a 4-year prospective study.** *Am J Infect Control* 2009, **37**(6):465-469.
58. Forster J, Guarino A, Perez N, Moraga F, Roman E, Mory O, Tozzi AE, de Aguilera AL, Wahn U, Graham C, Berner R, Ninan T, Barberousse C, Meyer N, Soriano-Gabarro M: **Hospital-based surveillance to estimate the burden of rotavirus gastroenteritis among European children younger than 5 years of age.** *Pediatrics* 2009, **123**(3):e393-e400.
59. Van Damme P, Giaquinto C, Maxwell M, Todd P, Van der WM: **Distribution of rotavirus genotypes in Europe, 2004-2005: the REVEAL Study.** *J Infect Dis* 2007, **195**(Suppl 1):S17-S25.
60. Banyai K, Bogdan A, Kisfali P, Molnar P, Mihaly I, Melegh B, Martella V, Gentsch JR, Szucs G: **Emergence of serotype G12 rotaviruses, Hungary.** *Emerg Infect Dis* 2007, **13**(6):916-919.
61. Grassi T, De Donno A, Guido M, Gabutti G: **G-genotyping of rotaviruses in stool samples in Salento, Italy.** *J Prev Med Hyg* 2006, **47**(4):138-141.
62. Giaquinto C, Van Damme P, Huet F, Gothefors L, Van der WM: **Costs of community-acquired pediatric rotavirus gastroenteritis in 7 European countries: the REVEAL Study.** *J Infect Dis* 2007, **195**(Suppl 1):S36-S44.
63. Giaquinto C, Van Damme P, Huet F, Gothefors L, Maxwell M, Todd P, da Dalt L: **Clinical consequences of rotavirus acute gastroenteritis in Europe, 2004-2005: the REVEAL study.** *J Infect Dis* 2007, **195**(Suppl 1):S26-S35.

#### Pre-publication history

The pre-publication history for this paper can be accessed here:  
<http://www.biomedcentral.com/1471-2334/11/9/prepub>

doi:10.1186/1471-2334-11-9

**Cite this article as:** Khoury *et al.*: Burden of rotavirus gastroenteritis in the Middle Eastern and North African pediatric population. *BMC Infectious Diseases* 2011 **11**:9.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

